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Abstract 
 
DOSE RESPONSE EFFECTS OF COGNITIVE-BEHAVIORAL THERAPY IN A RURAL 
SCHOOL MENTAL HEALTH PROGRAM 
 
Alex Kirk 
B.A. Hope College 
M.A. Appalachian State University 
 
Chairperson: Dr. Kurt D. Michael, Ph.D. 
 
School mental health (SMH) programs have been shown to be effective in providing 
empirically-based treatment to youth who otherwise might not receive treatment. However, a 
limitation of SMH programs is that they entail extended holiday breaks and typically do not 
operate over the summer, along with the fact that they often require pulling students from 
instruction time in order for them to receive therapy. These time limitations suggest that 
treatment needs to be expeditious and potent. Although researchers have investigated dose 
response to treatment, particularly for adult samples, no studies were located that addressed 
the question of dose response to treatment in SMH programs. The purpose of the present 
study was to address this gap in the literature by evaluating the dose response to SMH 
treatment in a sample of adolescents with diverse symptoms. Results showed an average total 
treatment response of a 26.81-point decrease in YOQ-30 score across 14 sessions of CBT. 
Further, adolescents exhibited reliable change (i.e., one of two RCI indicators) in YOQ-30 
score within an average of 2.91 sessions. Finally, it was found that baseline scores on the 
Depression and Hyperactivity subscales of the BASC-2, along with total YOQ-30 score, 
reliably predicted treatment response. These findings not only advance our understanding of 
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dose response to CBT in SMH settings, but they create opportunities to better inform, 
individualize, and prescribe effective treatment strategies in similar contexts.   
Keywords: school mental health, cognitive behavioral therapy, dose response  
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Abstract 
School mental health (SMH) programs have been shown to be effective in providing 
empirically-based treatment to youth who otherwise might not receive treatment. However, a 
limitation of SMH programs is that they entail extended holiday breaks and typically do not 
operate over the summer, along with the fact that they often require pulling students from 
instruction time in order for them to receive therapy. These time limitations suggest that 
treatment needs to be expeditious and potent. Although researchers have investigated dose 
response to treatment, particularly for adult samples, no studies were located that addressed 
the question of dose response to treatment in SMH programs. The purpose of the present 
study was to address this gap in the literature by evaluating the dose response to SMH 
treatment in a sample of adolescents with diverse symptoms. Results showed an average total 
treatment response of a 26.81-point decrease in YOQ-30 score across 14 sessions of CBT. 
Further, adolescents exhibited reliable change (i.e., one of two RCI indicators) in YOQ-30 
score within an average of 2.91 sessions. Finally, it was found that baseline scores on the 
Depression and Hyperactivity subscales of the BASC-2, along with total YOQ-30 score, 
reliably predicted treatment response. These findings not only advance our understanding of 
dose response to CBT in SMH settings, but they create opportunities to better inform, 
individualize, and prescribe effective treatment strategies in similar contexts.   
Keywords: school mental health, cognitive behavioral therapy, dose response  
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Dose Response Effects of Cognitive-Behavioral Therapy in a Rural School Mental 
Health Program 
It has been estimated that up to 49% of adolescents will be affected by a 
psychological disorder of at least mild impairment within their lifetime, with 27.6% of this 
group (i.e., 22.2% of all adolescents) experiencing a psychological disorder marked by severe 
impairment during their teen years (Costello, Copeland, & Angold, 2011; Merikangas et al., 
2010). Internalizing syndromes, broadly construed to include mood and anxiety disorders, are 
among the most common and debilitating psychological conditions during childhood and 
adolescence. It is estimated that 6.1% to 11.2% of children and adolescents will experience a 
mood disorder within their lifetime, while 8.3% to 10.7% will experience an anxiety disorder 
(Costello et al., 2011; Merikangas et al., 2010). Prevalence rates for externalizing conditions 
tend to be lower compared to internalizing problems, though they are still significant. Rates 
for severe cases of externalizing disorders range from 2.2% to 4% for conduct disorder, 3% 
to 4.2% for attention-deficit hyperactive disorder (ADHD), and 3% to 6.5% for oppositional 
defiant disorder (Costello et al., 2011; Merikangas et al., 2010). Finally, among adolescents 
who are impacted by a psychological disorder, 40% (i.e., roughly 20% of all adolescents) 
will meet criteria for two or more diagnoses (Merikangas et al., 2010). 
Both internalizing and externalizing conditions are associated with increased risk of 
impaired functioning in school, interpersonal problems, future psychological disorders, 
substance abuse, and suicidality (Birmaher et al., 1996). The presence of comorbid 
conditions can often complicate outcomes even further (Karlsson et al., 2006; Lewinsohn, 
Rohde, & Seeley, 1995; Newman, Moffitt, Caspi, & Silva, 1998). The high rate of 
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psychological disorders during adolescence is especially problematic when coupled with the 
barriers to accessing adequate mental health care. Some of the most common barriers 
preventing youth from receiving proper care include transportation problems, economic 
limitations, and the stigma associated with treatment seeking (Owens, Watabe, & Michael, 
2013; Zaheer et al., 2014).  
School Mental Health: Innovations in Treating Youth  
There is a growing body of literature that suggests a critical innovation in reaching a 
large number of youth is to treat them in school, where they spend the majority of their 
childhood (Farmer, Burns, Phillips, Angold, & Costello, 2003). Most children attend either a 
public or private school and are provided with reliable transportation, thus the school itself is 
an ideal environment for both the identification and provision of therapeutic interventions for 
mental health problems. This natural portal of entry into mental health treatment has been 
recognized in recent years, as independent groups have established school mental health 
(SMH) centers in public schools (e.g., Albright et al., 2013).   
As ideal as this might sound, however, the primary challenge for SMH is to provide 
services without placing undue burden on the educators or competing unnecessarily with the 
chief currency in schools (i.e., instruction time). Administrators and teachers are often 
hesitant to permit their students time during the school day to address issues that may not 
appear to be germane to education. However, it has been demonstrated that successful SMH 
partnerships work together with school personnel to establish symbiotic goals in the service 
of achieving improvements in psychological and academic outcomes (Albright et al., 2013; 
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Michael, Bernstein, Owens, Albright, & Anderson-Butcher, 2014; Owens, Murphy, 
Richerson, Girio, & Himawan, 2008; Owens et al., 2013).  
One of the main drawbacks of SMH programs is the reality that school is inherently a 
time-limited setting given the various breaks for vacations throughout the school year, along 
with the fact that most North American K-12 education systems operate on a nine-month 
school year. Such limitations highlight the need for efficient yet effective interventions and 
the importance of being able to determine how many sessions are necessary to produce 
meaningful therapeutic change in students’ symptoms and functional adjustment. Further, the 
primary challenge across SMH programs is to provide effective services without undue 
burden on instruction time, given that therapeutic interventions require the students to be 
pulled from classroom instruction. In light of this challenge, attempts to minimize the impact 
of lost instruction time are critical in sustaining SMH programs. In addition, from an 
empirical standpoint, it would be useful to know how many sessions are required in the 
context of a general SMH program to attain reliable change for the majority of those who 
undergo treatment.  It is also important to investigate other correlates that might help predict 
treatment dosage, such as problem type and the severity of the symptoms and issues being 
addressed. 
School Mental Health Outcomes  
 SMH programs have shown moderate to large effect sizes in reducing mental health 
symptomatology and problematic behaviors overall (Baskin et al., 2010; Baskin, Slaten, 
Sorenson, Glover-Russell, & Merson, 2010; Prout & DeMartino, 1986; Prout & Prout, 1998). 
Previous research using school-based samples of K-12 students and their families found that 
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SMH services can effectively treat both internalizing and externalizing problem behaviors, 
buffer general emotional distress, and improve academic outcomes such as standardized test 
scores and discipline referrals (Berry & Hunt, 2009; Fox et al., 1999; Michael et al., 2013; 
Sander, Everts, & Johnson, 2011).  
Some meta-analytic studies have shown moderately beneficial effects from a SMH 
program utilizing cognitive-behavioral therapy (CBT), specifically in alleviating both 
depressive and anxiety symptoms in children and adolescents (Kahn, Kehle, Jensen, and 
Clark, 1990; Prout & DeMartino, 1986; Prout & Prout, 1998; Reynolds & Coats, 1986; 
Swannell, Hand, & Martin, 2009). Similarly promising results have been found for SMH 
programs in the treatment of ADHD (Owens et al., 2012; Watabe, Stewart, Owens, Andrews, 
& Griffeth, 2012). Further, SMH programs have been utilized not only to treat psychological 
disorders but also to prevent psychological symptoms from reaching clinical levels (Albright 
et al, 2013; Ballard, Sander, & Klimes-Dougan, 2014; Swannell, Hand, & Martin, 2009). 
Finally, and relevant to the current study, previous outcome research in western North 
Carolina shows that a SMH approach within a rural context (Albright et al., 2013) is of 
comparable effectiveness to those receiving treatment for similar ailments in other contexts 
(TADS, 2007; Walkup et al., 2008).  
Dose Response to Treatment 
The dosage model for psychotherapy, initially introduced by Howard, Kopta, Krause, 
and Orlinsky (1986), attempts to measure the therapeutic effect for varying doses of 
psychological treatment, where “dose” is measured by the number of sessions a client attends 
and “effect” is measured by the proportion of clients who improve. This same study suggests 
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that more psychotherapy generally results in a greater probability of improvement, though 
this resembles a curvilinear relationship where higher doses of treatment yield reduced 
therapeutic gains over time (Howard et al., 1986). 
Much of the research looking at dose response to treatment has measured clinical 
progress using a Reliable Change Index (RCI; Jacobson & Truax, 1991). Researchers utilize 
this standardized metric to measure clinically relevant change, calculating the number of 
sessions required to produce this change. Jacobson and Truax (1991) suggest that if the 
amount of observed change exceeds a certain threshold, based on the measure being used and 
at the desired level of significance, then one has shown “reliable change.” This RCI 
calculation involves two parts. First, the individual must begin treatment within the clinical 
range of symptom severity; and then, the individual must end treatment in a non-clinical 
range. The second part of this RCI calculation determines whether an individual’s change in 
symptom severity from a clinical range to non-clinical range is of a reliable quantity (i.e., 
amount) of change and not merely a chance fluctuation. 
Based on these two conditions, individuals who drop a reliable amount in symptom 
level between initial and final assessment and move from a clinical to non-clinical range are 
labeled as “recovered.” Individuals who drop a reliable amount in score between initial and 
final assessment but remain in the clinical range are labeled as “improved.” Clients who do 
not see reliable change in scores are deemed “unchanged.” Finally, for individuals who see a 
reliable increase in score between initial and final assessment scores would be labeled 
“deteriorated.”  
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Unfortunately, most of the literature where dose response to treatment has been 
examined focuses on adults. Lambert et al. (1996) examined the treatment response in a 
sample of adults who were deemed to have a range of clinically significant symptoms based 
on pre-treatment Outcome Questionnaire (OQ) scores. The results of this study suggest that 
by the end of session five, 25% of this sample could expect to be recovered based on 
Jacobson and Truax (1991) criteria, and 50% would be expected to recover by session 11 
(Anderson & Lambert, 2001). A study of 47 adults with similar symptom profiles and levels 
of impairment found that a higher dosage of psychotherapy was required, where 25% 
recovered by the end of session 10, 50% recovered by session 16, and 75% by session 25 
(Kadera, Lambert, & Andrews, 1996). In a more comprehensive published review, Hansen, 
Lambert, and Forman (2002) found that roughly 57.6% of adult psychotherapy clients would 
expect to be recovered after an average of 12.7 sessions, while 67.2% would expect to be 
recovered or improved. However, in the same review the authors reported that the average 
number of sessions received among 6,000 psychotherapy clients in naturalistic settings was 
less than five, resulting in a rate of improvement of roughly 20%, suggesting that, on 
average, most individuals receive an inadequate number of sessions to achieve a positive 
treatment response. Additional research suggests that, for the typical adult outpatient 
psychotherapy client, roughly one year of psychotherapy is required in order to have a 75% 
chance of symptom recovery (Kopta, Howard, Lowry, & Beutler, 1994). 
 A study that measures treatment response based on dosage for adolescents receiving 
CBT in the context of a SMH program was not found in the published empirical literature. 
As such, the primary aim of this study is to address the question of how much treatment is 
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necessary to provide a reasonably effective response, as defined by reliable change, for the 
average student who presents for individual CBT with elevated internalizing or externalizing 
symptoms in a SMH program. Further, the secondary goal is to then determine whether pre-
treatment scores on the Behavior Assessment System for Children, 2
nd
 Edition (BASC-2; 
Reynolds & Kamphaus, 2004) and Youth Outcome Questionnaire (YOQ-30; Burlingame et 
al., 2004) can predict slope change on the YOQ-30 across time.  
Given that dosage effects have not been studied extensively in adolescents with 
diverse symptoms and comorbidities or in the context of a SMH paradigm, it is difficult to 
make precise predictions. However, the literature provides some general guidance. For 
instance, Baldwin and colleagues found that in an adult sample of 4,676 psychotherapy 
clients in naturalistic settings, clients attended an average of 6.46 sessions of psychotherapy 
where roughly 43% of clients achieved clinically significant change (Baldwin, Berkeljon, 
Atkins, Olsen, & Nielsen, 2009). Further, Baldwin et al. (2009) found that 50% of clients 
who received 10 sessions of outpatient psychotherapy (n = 50) attained clinically significant 
change. With respect to SMH treatment in particular, Albright et al. (2013) provided CBT to 
a sample of 58 adolescents with a mixture of internalizing and externalizing problems. 
Albright et al. (2013) reported that 63% of the adolescent sample was either improved or 
recovered by the end of treatment, with an average of roughly 15 sessions per student whose 
baseline score was in the clinical range.  
However, these SMH researchers did not measure treatment response over time 
beyond reporting the average dosage. Moreover, there was no way to determine the impact of 
other variables on dosage such as the level of psychological distress at baseline, highlighting 
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the importance of the current study determining whether pre-treatment assessment scores on 
the BASC-2  and YOQ-30 can predict treatment response over time. In an example of this 
approach, Michael and Furr et al. (2009) studied individual differences at baseline and the 
impact of psychotherapy outcomes in a young adult sample and reported that clients who 
presented with above average levels of psychopathology at pre-treatment as measured by the 
MMPI-2 (i.e., one standard deviation above the sample mean) exhibited almost half the level 
of symptom reduction per session when compared to clients with average levels of 
psychopathology at baseline. Other research has attempted to determine whether symptom 
profiles at baseline assessment are predictive of treatment response. Indeed, Kopta et al. 
(1994) found that 50% of clients with acute distress (i.e., short-term anxiety, somatization, 
depression, and compulsions) at baseline tended to see clinically meaningful change by 
session five, whereas 50% of those with chronic distress (i.e., long-lasting anxiety, phobias, 
depression, and obsessions) required approximately 14 sessions or more to produce similar 
outcomes. So, in this adult study, there was an apparent interaction between average 
treatment response and level of distress exhibited by the client at baseline. 
Given the dearth of research that addresses treatment dosage response for adolescents 
in SMH programs, clinicians working in such settings have few, if any, tools available to 
accurately predict treatment response for these populations. Given this gap in the literature, 
one of the aims of the current project is to determine whether baseline scores on the YOQ-30 
and BASC-2 can predict therapeutic response based on YOQ-30 slope change over the 
course of treatment for adolescents receiving mental health services in a SMH program. 
Knowing more about the slope change in YOQ-30 scores would help estimate how many 
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sessions are required before adolescents attain clinically significant change, and further, how 
much an adolescent might expect to improve over an entire course of treatment (e.g., 14 
sessions) as defined by a total drop in YOQ-30 score. 
Based on the research pertaining to adults discussed above, approximately 50% of a 
given treatment sample typically demonstrates clinically significant change after an average 
of 11-16 sessions (Anderson & Lambert, 2001; Hansen, Lambert, & Forman, 2002; Kadera, 
Lambert, & Andrews, 1996). Consequently, it was hypothesized that reliable change (i.e., 
one of the RCI indicators) would be evident, on average, by session 12 among our sample. 
Thus, this study should help to clarify the differences in treatment response between 
adolescents and adults, and more specifically for adolescents receiving SMH services. 
Method 
Participants 
Participants were 133 high school students between the ages of 14 and 18 years old 
(M = 15.96, SD = 1.29) served by the Assessment, Support, and Counseling (ASC) Center 
between fall 2011 and fall 2014. Of this sample, 63.9% (n = 85) were female. Students were 
referred to the ASC Center primarily by professional school counselors and administrators. 
Other sources of referrals included parents, community providers, and self-referrals. Students 
who were 18 years or older provided their own legal consent, while those younger than 18 
years old provided the written consent of their legal guardian(s) as well as their own assent. 
Inclusion for this study required three or more therapy sessions, a clinically elevated baseline 
YOQ-30 (i.e., defined by a score of 29 or higher; Burlingame et al., 2004), a post-treatment 
YOQ-30, and a pre-treatment BASC-2. 
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Procedure  
 The process of data collection began with obtaining baseline measures to each student 
participant once he or she voluntarily enrolled and provided informed consent (and assent) 
for ASC Center services. Consent to treat and consent to participate in research were 
collected separately as treatment is not contingent upon research participation. Upon 
admittance into ASC Center services, baseline information was collected immediately. For 
measures of emotional, behavioral, and cognitive functioning, the timing of baseline was 
therefore defined as the date of ASC Center treatment initiation. Baseline measures included 
the YOQ-30 and BASC-2 self-report form. In addition, the YOQ-30 was administered once 
every week or every other week as individual cases and treatment plans would allow.  
 Treatment consisted of non-manualized CBT along with crisis intervention and case 
management whenever appropriate, depending on the student and the severity of presenting 
problems. The therapists providing treatment were predominantly Masters-level licensed 
psychological associates (LPA) and clinical psychology graduate students. All of these 
therapists were under the supervision of a licensed clinical psychologist with a CBT 
orientation. All data for the duration of treatment was anonymized by assigning a number to 
each student within the data set.  
Measures 
YOQ-30. The Youth Outcome Questionnaire (YOQ-30; Burlingame et al., 2004) is a 
self-report measure that is used to measure recent emotions, behaviors, and thoughts, and was 
used herein to track changes in these dimensions of psychological well-being during the past 
week. This measure consists of 30 questions which are rated on a 4-point Likert scale 
DOSE RESPONSE EFFECTS  13 
 
 
 
comprised of never (0), rarely (1), sometimes (2), and always or almost always (3); each 
option refers to the frequency of occurrence of the respective symptom. Students were given 
a YOQ-30 at the start of services with the ASC Center and at least every two sessions 
thereafter. Any score at or above 29 on the YOQ-30 is suggestive of clinically significant 
psychological symptoms. In addition, a change of 10 points between two YOQ-30 scores 
qualifies as “reliable change” (Burlingame et al., 2004). Thus, a difference of 10 or more 
points between two YOQ-30 scores suggests that treatment had a causative impact on 
symptom change, where an increase by 10 or more points suggests symptom deterioration 
and a like decrease suggests improvement. 
BASC-2. The Self-Report of Personality (SRP-A) form of the Behavior Assessment 
System for Children, 2
nd
 Edition (BASC-2; Reynolds & Kamphaus, 2004) was used to 
measure emotional and behavioral functioning. The SRP-A is comprised of 176 questions 
where only a true or false response is required, along with questions which operate on a 4-
point Likert scale comprised of never, sometimes, often, or almost always; each referring to 
the frequency which the behavior in question occurs. A score between 60 and 69 signifies an 
“at risk” score, while any score of 70 or higher qualifies as “clinically elevated.” The SRP-A 
form exhibits high internal consistency on its composite scales (α = 0.84 – 0.96) and 
adequate test-retest reliability (0.71 – 0.82), suggesting strong support in the literature for the 
use of the BASC-2 as a reasonably sensitive outcome measure (McClendon et al., 2011; 
Reynolds & Kamphaus, 2004). 
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Analyses 
 The answers to three empirical questions will be sought in this study including 1) how 
much an adolescent might improve, on average, over a regimen of CBT based on YOQ-30 
score change, 2) what dosage (i.e., number of sessions) of CBT is required for the average 
adolescent to demonstrate improvement as measured by a 10-point reduction in YOQ-30 
total score from baseline to post-treatment, and 3) whether baseline scores on the YOQ-30 
and BASC-2 can reliably predict treatment response. The chosen statistical analysis will be 
random intercepts/random slopes multilevel modeling (MLM), run through Statistical 
Package for the Social Sciences (SPSS) version 22. MLM was chosen given its utility in 
measuring slope change across time and for its ability to predict values for missing data, both 
of which are relevant in the present study. A YOQ-30 change score variable will be 
calculated for the sample, defined as the difference between any given YOQ-30 across the 
duration of treatment and the baseline YOQ-30. This change score variable will serve as the 
outcome for all MLM as the main focus will be to assess slope change across time in this 
YOQ-30 change score variable and then to determine whether baseline scores on the BASC-
2 or YOQ-30 can accurately predict that slope change.  
However, the initial baseline YOQ-30 change score for each participant will not be 
used in outcome analyses, given that everyone will start with a score of zero (i.e., the 
difference between the baseline YOQ-30 score, administered at session one, with itself), 
which would yield an intercept absent of any practical meaning as it would be interpreted as 
no YOQ-30 change at session one. As such, the YOQ-30 change score at session two will be 
treated as the new baseline YOQ-30 change score across the sample, and all outcome 
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analyses will be based on YOQ-30 change scores at session two and after. By doing this, the 
new intercept (i.e., when time is zero) for each participant will be defined by the session two 
change score providing a meaningful interpretation of the intercept (i.e., the average amount 
of YOQ-30 change predicted by session two). Additionally, this will allow participants to 
vary at baseline, thereby indicating the random intercepts procedure. Further, using a random 
intercepts approach will allow for analytic procedures which can determine how the 
variability with each analysis, and the inclusion of different predictors, will be partitioned. 
The random slopes analysis was chosen so each participant’s rate of change can be 
allowed to vary based on idiosyncratic YOQ-30 change scores over time as rates of change 
are not commensurate across the sample. As such, a random slopes analysis will be used to 
assess the extent to which average YOQ-30 change score varies among participants and 
across time. Therefore, the purpose of MLM is to determine slope change between each 
YOQ-30 over time, whereby a positive slope indicates a decrease in symptom severity and a 
negative slope indicates an increase in symptom severity. 
General response to treatment. In order to satisfy the first aim of the study, a base 
model will be constructed consisting solely of the YOQ-30 change score variable. By 
excluding time variables and predictors, the intercept value obtained from this base model 
would thus represent the average total amount of change that participants would expect 
across the entirety of treatment. That is, the total number of points which adolescents would 
expect YOQ-30 score to drop, on average, throughout the duration of CBT.  
In addition, this base model will allow us to assess the amount of variability observed 
before adding predictors into the model at later steps in order to draw more meaningful 
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comparisons of how much variance is assumed by each predictor in subsequent models. Once 
this initial base model is constructed and analyzed, random intercepts will then be added. 
This will allow us to look at the average amount of YOQ-30 score change throughout the 
entirety of treatment when scores are allowed to vary, as compared to the base model where 
scores are fixed. While this aim will provide meaningful information, it does not fully 
address the dosage component of this study, which is highlighted by the second aim. 
Dose response to treatment over time. Following the assessment of general 
response to treatment, the time element will be incorporated into the base model so dose 
response can be further assessed. While the base model will yield a prediction of average 
total change, it will be unable to predict the amount of YOQ-30 change expected by each 
session. However, this study will attempt to determine the number of sessions required to see 
reliable change as defined by a decrease of 10 points or more on the YOQ-30 (i.e., one of 
two RCI criteria), thus satisfying the second aim of the study and subsequently providing 
results relevant to the hypothesis. Further, when incorporating the time element (i.e., session 
number data), we will assess for the presence of time interaction terms (e.g., quadratic time 
patterns), which would suggest a non-linear slope pattern, indicative of varying rates of 
symptom change across time. In order to yield more clinical utility, however, clinicians need 
to be able to predict treatment response based on pre-treatment measure scores, thus 
providing a rationale for the third and final aim of the present study. 
Predicting treatment response. After constructing a model to calculate overall 
treatment response (i.e., the first aim of the study) and dose response to treatment (i.e., the 
second aim of the study), grand mean-centered level-2 predictor variables will be added in 
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order to determine whether YOQ-30 or BASC-2 subscale scores can predict treatment 
response. The purpose of this will be to assess whether baseline patterns of score elevations 
on the YOQ-30 and BASC-2 can predict when a participant would improve by 10 points on 
the YOQ-30. The BASC-2 subscales tested for these analyses will include Atypicality, Locus 
of Control, Social Stress, Anxiety, Depression, Sense of Inadequacy, Somatization, Attention 
Problems, and Hyperactivity. These were chosen given their clinical nature in symptom 
profiles, and because their items are distinct from one another thus avoiding problems with 
multicollinearity. Grand mean centering will be used on level-2 predictors given its utility 
when focusing on level-2 predictors while controlling for the level-1 covariate (i.e., session 
number), dealing with potential multicollinearity among predictor variables, and to make 
lower-order effects more interpretable when dealing with interaction terms (Enders & 
Tofighi, 2007).  
The YOQ-30 baseline score will be the first predictor added to the model as it is a 
separate measure from the BASC-2 and is hypothesized to be among the stronger predictors 
given that it would likely be correlated with YOQ-30 change score. Next, all BASC-2 
subscale scores will be added to the model at once. The BASC-2 subscale with the highest p-
value will be removed iteratively in a backward stepwise approach, with analyses run again 
upon each removal. This will be done in the event that removing subscales one at a time 
might result in another assuming a significant portion of the variance. This procedure will be 
used in order to find the cumulative effect of BASC-2 baseline scores. That is, when BASC-2 
subscales are added to the model one at a time, certain subscales may be less significant or 
entirely nonsignificant and subsequently could be overlooked from the model. However, 
DOSE RESPONSE EFFECTS  18 
 
 
 
when incorporated with other subscales, their combined effects could prove to be significant 
and thus meaningful for model incorporation. 
As such, this final analysis will entail an equation prediction model with grand mean-
centered measure scores consisting of all meaningful pre-treatment scales. The purpose of 
utilizing pre-treatment BASC-2 subscales and YOQ-30 scores in this way is to test for 
treatment response predictions based on pre-treatment scores (i.e., whether a difference in 
pre-treatment BASC-2 subscale scores or YOQ-30 score could predict a change in the slope 
of YOQ-30 change score over time). As such, the ultimate aim will be to determine whether 
elevations on the YOQ-30 or BASC-2 can predict the number of sessions needed for an 
adolescent to exhibit reliable change on the YOQ-30 (i.e., improve YOQ-30 score by 10 
points). 
Results 
 Means and standard deviations for baseline BASC-2 subscale T-scores are provided 
in Table 1. Average baseline subscale scores, with the exception of Hyperactivity, are 
classified as at-risk, indicated by a T-score between 60 and 69. Hyperactivity, however, 
showed an average score of 57.48 (SD = 11.11), which is classified as non-clinical. In 
addition, the frequencies for both at-risk and clinically elevated (i.e., T-score of 70 or more) 
baseline BASC-2 scores are displayed for each subscale in Figure 1. Taken together, these 
results indicate greater frequencies of internalizing pathology relative to externalizing 
pathology, with greater symptom severities in Anxiety and Depression, suggesting that the 
present SMH program treated students struggling with internalizing symptoms more than 
those with externalizing symptoms.  
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General Response to Treatment 
The average number of sessions among participants was 14.79 (SD = 9.66), ranging 
from 3 to 55 sessions. However, not all session data were used in the analyses for two 
reasons: the YOQ-30 was not administered every session for each participant, and the 
number of participants in active treatment declined markedly over time. As a result, the 
amount of missing data increased with each subsequent session. While MLM can account for 
missing data by estimating parameters with the available data, the accuracy of this procedure 
decays as more data are missing. As such, it was decided that all data up to session 14 would 
be used for analyses given that it was the mean number of sessions in both this study and in 
past research on the present SMH program (Albright et al., 2013), and to ensure that 
sufficient data were available to warrant confidence in the missing data procedures via MLM. 
As such, it was found that 45.11% of participants were still in active treatment at session 14. 
Further, out of the 133 participants within the sample, 25.56% had a YOQ-30 change score at 
session 14 available for analyzing. Upon limiting the number of sessions to 14, the mean 
became 10.86 (SD = 3.67). 
 The findings pertaining to the first aim of the study (i.e., total amount of 
improvement across the duration of treatment) were significant, F(1, 764) = 742.16, p < .001. 
Here, the average amount of total change in YOQ-30 score across 14 sessions of CBT was 
defined by a decrease of 16.65 points, b = 16.65, t(764) = 27.24, p < .001 (Table 3, Model I). 
Initial -2 Log Likelihood (-2LL), an indication of model fit by estimation of error variance, 
for this base model was 6487.23, indicating the extent of error, along with a residual estimate 
of 285.22 (p < .001; Table 2, Model I).  
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Model II (i.e., the incorporation of random intercepts) proved to be statistically 
significant as well, F(1, 132.03) = 165.01, p < .001 (Table 2). Based on the results from 
Model II (Table 2), the average amount of total change in YOQ-30 score throughout the 
duration of treatment was defined by a decrease of 15.94 points, b = 15.94, t(132.03) = 12.85, 
p < .001 (Table 3, Model II), or about 0.71 points less than the results from Model I. 
Following the inclusion of random intercepts, a significant decrease in -2LL error variability 
was observed, χ
2
 (1) = 497.82. Further, residual variance decreased to 99.65 (p < .01), 
indicating a drop of 65.1% (Table 2, Model II), and thus Model II was assumed to be more 
robust relative to the base model. 
When applied to the average baseline YOQ-30 score for the sample, this figure of a 
15.94 point decrease on the YOQ-30 would predict an average final YOQ-30 score of 32.44. 
This suggests that the majority of our sample would be “improved,” or meet half of the RCI 
criteria, before the end of the 14 sessions. However, this does not satisfy the hypothesis of 
this study, which is the purpose of the second aim (i.e., measuring dose response to 
treatment).  
Dose Response to Treatment over Time 
Results from the inclusion of session number data showed that linear, F(1, 646.80) = 
29.35, p < .001 (Table 2, Model IV), quadratic, F(1, 592.20) = 7.223, p < .01 (Table 2, 
Model V), and cubic, F(1, 582.13) = 4.532, p < .05 (Table 2, Model VI) time trends were 
found to be significant and therefore retained for the addition of level-2 predictors. Specific 
rates of change suggest a positive slope for the linear, b = 3.71, t(646.80) = 4.95, p < .001, 
and cubic, b = 0.16, t(582.12) = 2.13, p < .05, trends, and a negative slope for the quadratic 
DOSE RESPONSE EFFECTS  21 
 
 
 
trend, b = -0.37, t(592.20) = -2.69, p < .01 (Table 3, Model IV). As such, both linear and 
cubic trends illustrated a decrease in symptoms, while the quadratic trend exhibited an 
increase in symptoms.  
This pattern of slope change suggests an improvement in symptoms at non-linear 
rates across time. More specifically, there is an immediate decrease in symptoms exhibited 
by a positive slope, which begins to decline steadily after session two and through session 
nine on account of the quadratic term, thus indicating a diminishing return on symptom 
improvement. By session ten, the slope begins to increase again and steadily grows for the 
duration of treatment, suggesting a return to more rapid symptom improvement as a result of 
the cubic term. As such, these results indicate a non-linear growth curve with a cubic time 
effect, illustrating three changes in slope trend, whereby an average of 2.91 sessions 
predicted a decrease of 10 points on the YOQ-30 across the sample (Figure 2), signaling one 
of the two reliable change indicators. Thus, this finding confirms our hypothesis as students 
exhibited reliable change on the YOQ-30 within 12 sessions of CBT. 
Interestingly, once the time element was added to Model II, not only was there a 
significant decrease in error variance (Table 2, Model VI), but also the predicted average 
amount of total YOQ-30 change for the sample across 14 sessions of CBT was 26.81 points; 
more than ten points greater than what Model I (i.e., base model) and Model II predicted. 
This suggests that, on average, the final YOQ-30 score for our sample would be 21.57. 
Compared to the finding from Model II of the first aim of this study, which predicted that 
adolescents would meet RCI improvement criteria across 14 sessions of CBT on average, 
Model VI (i.e., incorporating session data) updated this finding by predicting that adolescents 
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would in fact meet recovery criteria across 14 sessions of CBT on average. In fact, even more 
specific findings can be drawn from this time model as it was predicted that, on average, 
participants would see a drop of 19.49 points on YOQ-30 score by session eight, which 
would yield a YOQ-30 score of 28.89. This indicates both a decrease of more than 10 points 
(i.e., reliable change) and a shift from a clinical to non-clinical score. As such, not only 
would the average participant exhibit recovery criteria by session 14, but recovery would also 
actually occur by approximately session eight on average. 
Predicting Treatment Response 
The final aim of the study was to determine whether baseline measures could predict 
treatment response. First, baseline YOQ-30 score was found to be significant when 
incorporated into the model, F(1, 131.96) = 32.815, p < .001, suggesting it could predict 
YOQ-30 slope change across sessions. Further, two BASC-2 subscales were retained in the 
model following the iterative removal of nonsignificant subscales: Depression and 
Hyperactivity (Table 4). While Depression was statistically significant in predicting 
treatment response, F(1, 131.24) = 14.72, p < .001, Hyperactivity was not, F(1, 128.17) = 
3.654, p = .058. Hyperactivity was still retained for analyses despite being nonsignificant 
given the probable likelihood it would have been statistically significant had there been 
greater statistical power via a larger sample size, coupled with the notion that the .05 cut-off 
value, which the Hyperactivity subscale missed by a narrow margin, is often perceived as 
being arbitrary. Both of these illustrate commonly cited limitations of null hypothesis 
significance testing (Cohen, 1994).  
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Results of this final model indicated that baseline YOQ-30 score illustrated a positive 
slope, b = 0.54, t(131.96) = 5.728, p < .001, while baseline scores for Depression, b = -0.41, 
t(131.24) = -3.836, p < .001, and Hyperactivity, b = -0.19, t(128.17) = -1.912, p = 0.58, 
revealed negative slopes (Table 3). Such trends suggest that a higher baseline YOQ-30 score 
is predictive of more immediate symptom improvement, while relatively higher baseline 
scores on the Depression and Hyperactivity BASC-2 subscales are predictive of worsened 
symptom response. 
Finally, a significant decrease of 12.1% in -2LL was observed in the final model (i.e., 
Model VIII) relative to the base model (i.e., Model I), χ
2
 (8) = 785.2, p < .01. In addition, the 
residual estimate decreased by 229.98 between the base model (i.e., Model I) and the final 
model (i.e., Model VIII), representing an 81% decrease. These results suggest that our final 
model contained significantly less error than our base model and that significantly greater 
variance could be attributed to both the time element and the predictor variables (Table 2, 
Model VIII). 
Discussion 
The answers to three empirical questions were sought in this study including 1) how 
much an adolescent might improve, on average, over 14 sessions of CBT based on YOQ-30 
scores, 2) what dosage (i.e., number of sessions) of CBT was required for the average 
adolescent to demonstrate improvement as measured by a 10-point reduction in YOQ-30 
score from baseline to post-treatment, and 3) whether baseline scores on the YOQ-30 and 
BASC-2 could reliably predict treatment response. The findings pertaining to each of these 
research questions are discussed in sequence below.  
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General Response to Treatment 
It was found that the average adolescent within our sample would be recovered (i.e., 
meeting both RCI criteria) after 14 sessions of CBT. This is consistent with previous SMH 
literature (Albright et al., 2013; Kahn, Kehle, Jensen, & Clark, 1990; Prout & DeMartino, 
1986; Prout & Prout, 1998; Reynolds & Coats, 1986; Swannell, Hand, & Martin, 2009) and 
large-scale randomized controlled trials (TADS, 2007; Walkup et al., 2008). However, this 
general finding about outcome prediction is based solely on prediction models which do not 
take session data or other predictors into account. While these results are indeed promising 
for adolescents receiving treatment in SMH settings, they do not provide more specific 
predictions for when an adolescent would expect recovery to occur in terms of the actual 
session number. The findings pertaining to dose response and baseline predictors will be 
discussed in the following two sections. 
Dose Response to Treatment over Time 
The second aim of this study was to measure treatment response as defined by the 
number of sessions (i.e., dosage) required to observe a 10-point improvement on the YOQ-
30. This aim was germane to the hypothesis about dose response, which predicted that the 
average student would evidence a 10-point decline on the YOQ-30 by session 12. 
Implementing session number data into the base model allowed for treatment response to be 
broken down by session. Once this information was included in the model, a non-linear, 
cubic curve was observed. The finding suggests that, on average, participants did not 
improve at a steady rate. Instead, the pattern of improvement appears to first accelerate, then 
flatten, and then increase again across the 14 sessions of CBT (Figure 2).  
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One of the more striking findings is the relatively rapid rate of change within the first 
three sessions, given that the average participant met one of two reliable change indicators, as 
defined by a drop of 10 points or more on the YOQ-30. This finding supports the dose 
response hypothesis, where it was predicted that one of the reliable change indicators would 
be evident, on average, by session 12. Therefore, not only was there support for the dosage 
hypothesis, but when compared to previous findings on dose response effects of therapy 
(Anderson & Lambert, 2001; Hansen et al., 2002; Kadera et al., 1996), the results were 
achieved in less time than is typically seen in adult studies ranging from 5 to 16 sessions of 
psychotherapy (Anderson & Lambert, 2001; Connolly et al., 2011; Kadera et al., 1996). The 
rate of improvement reported here is consistent with one of the definitions of “sudden gains” 
observed in psychotherapy, where there is at least a 25% reduction in pre-gain symptoms 
(Tang & DeRubeis, 1999).  
Indeed, the rapid improvement from CBT relative to other therapies is well-
documented in the adult literature (Aderka, Boe, Nickerson, & Hofmann, 2012; Hollon & 
Ponniah, 2010; Picardi & Gaetano, 2014). The present study provides yet more evidence of 
rapid improvement from CBT and is one of the first to document these effects in the 
adolescent literature and particularly when delivered in SMH contexts. This finding directly 
addresses one of the main concerns often expressed by school administrators and teachers, 
where treating students during the school day is seen as tantamount to lost instruction time, 
rather than an expenditure of resources possibly associated with better learning outcomes. 
Based on the available results, clinicians might expect the average student to show 
improvement in a relatively few number of sessions, similar to the results from adult studies, 
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and subsequently resulting in little interference with academics. Though speculative, an 
explanation for the rapid responding seen in this study might be attributable to the treatment 
modality of CBT. Indeed, in a recent meta-analysis, Aderka, Nickerson, Boe, and Hoffmann 
(2012) studied the sudden gains hypothesis in a meta-analysis of depression and anxiety 
treatment studies and found that the effect size (ES) or magnitude of sudden gains was more 
pronounced in CBT (ES = 0.75) than in non-CBT (ES = 0.23) interventions. 
While the first aim of this study provided the finding that participants would expect to 
be recovered after 14 sessions of CBT, the results attained from the second aim of this study 
were able to provide more precise predictions for when recovery would occur on average. 
Here, the incorporation of session data predicted that students would exhibit recovery 
criteria, on average, by session eight. Overall, these data suggest that a response to CBT in 
the context of a SMH program is not only rapid for many who undergo treatment, but the 
benefits can be achieved well within the time frame of a typical academic year, even when 
providing intervention to youth with clinically significant problems including depression and 
suicidal ideation (Kirk, Jameson, Michael, & West, 2014). These results mirror the findings 
of Spirito et al. (2011) who reported that positive results were achieved after approximately 8 
sessions, including many who presented with similarly significant symptoms. Taken 
together, the findings presented here suggest that SMH programs are effective and feasible 
treatment paradigms capable of producing results in relatively short time frame. In addition 
to the dose response findings, the results regarding the predictive power of baseline YOQ-30 
and BASC-2 scores were the third aim of the study and equally intriguing.  
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Predicting Treatment Response 
 The third aim of this study was to determine whether baseline measures could predict 
treatment response, specifically the YOQ-30 and nine clinical BASC-2 subscales (i.e., 
Atypicality, Locus of Control, Social Stress, Anxiety, Depression, Sense of Inadequacy, 
Somatization, Attention Problems, and Hyperactivity). Of interest were the divergent slope 
patterns between the YOQ-30 and BASC-2 Depression and Hyperactivity subscales. While a 
relatively higher baseline score on the YOQ-30 indicated more rapid symptom improvement, 
higher scores on the Depression and Hyperactivity subscales were associated with a 
worsened treatment response. The YOQ-30 slope pattern might be explained by two 
phenomena in particular. First, baseline YOQ-30 scores will correlate with YOQ-30 change 
scores given that each are based on the same measure. Second, a higher baseline YOQ-30 
score creates more room for regression to the mean. That is, having the lowest possible 
clinical score on the YOQ-30 (i.e., 29 points) may imply less room for rapid change, whereas 
having a relatively high score on the YOQ-30 (e.g., 101, the highest score within the present 
sample) suggests more room for rapid improvement. In the former case, the individual is 
significantly closer to the likely mean YOQ-30 score for the general population. In the latter 
case, however, the individual is significantly farther away and thus will likely see a more 
rapid change in score, at least initially. Interestingly this second explanation would diverge 
from previous findings on sudden gains, as pre-treatment levels of symptom severity for 
those who have demonstrated rapid improvement in past studies were generally lower (Tang 
& DeRubeis, 1999). However, in this case, the opposite was found, as relatively higher levels 
of YOQ-30 severity predicted more rapid improvement. 
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 The findings regarding the Depression and Hyperactivity BASC-2 subscales suggest 
that relatively higher scores at pre-treatment predict a slowed treatment response. These 
findings are consistent with previous literature (e.g., Michael & Furr et al., 2009), where a 
higher level of psychopathology at baseline predicts a longer course of treatment necessary to 
produce either improvement or recovery for the participants. In this instance, it was 
interesting that one internalizing and one externalizing clinical scale provided the most 
predictive utility for the sample for two reasons. First, the sample under study had a general 
mixture of internalizing and externalizing problems, many of whom presented with 
significant elevations in these areas. Thus, these findings will likely prove useful in 
prescribing treatment dosage across a diverse array of symptom presentations. Second, 
although a diagnosis is not required to receive treatment at the ASC Center, the findings 
might speculate that particular features cutting across diagnostic categories are associated 
with outcome and should be considered as potential treatment targets. Further research is 
required to better understand these observed patterns. 
Implications 
 The purpose of this study was driven heavily by practical questions in SMH 
treatment. That is, how many sessions might a clinician expect to have with an adolescent 
before reliable change is likely, and can we predict response based on pre-treatment 
measures? The benefits of these findings are such that clinicians can plan a course of 
treatment informed by objective data regarding when to expect achieving certain benchmarks 
(e.g., improvement, recovery). In other words, the study provides an empirically-based 
framework for SMH treatment-planning. In this case, the two most meaningful implications 
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are that 1) the average adolescent exhibits half of the reliable change indicators by the third 
session and recovery by the eighth session and 2) those with relatively higher scores on the 
Depression and Hyperactivity BASC-2 subscales will require a longer course of treatment to 
exhibit reliable change while those with relatively higher scores on the YOQ-30 will require 
a shorter course of treatment to similarly exhibit reliable change.  
In line with the second major implication is the creation of a basic algorithm which 
can predict treatment response (see Figure 3). When a clinician obtains student data for the 
BASC-2 and YOQ-30, that clinician can simply input the scores into an algorithm and find 
the predicted amount of average YOQ-30 change by session. For example, when the baseline 
Depression and Hyperactivity BASC-2 subscale scores are average within our sample (i.e., 
66 and 57, respectively) and a student’s baseline YOQ-30 score is 40, then we would expect 
improvement by roughly session five and recovery by session six. When adjusting this 
scenario so the baseline YOQ-30 score is 50, we would expect improvement by session 3 and 
recovery by session 10. With a YOQ-30 baseline score of 60 and average scores on the 
Depression and Hyperactivity BASC-2 subscales, we would then expect recovery by session 
14. In terms of treatment planning and goals, these examples highlight that a higher pre-
treatment YOQ-30 score predicts a quicker time to exhibit “improvement,” which is a static 
metric defined by a change of 10 points or more regardless of one’s clinical magnitude, but 
often a longer time to exhibit “recovery,” a more dynamic metric as those with higher scores 
start treatment further away from a non-clinical score meaning they have more therapeutic 
ground to cover in order to be classified as non-clinical.  
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As a reminder, these predictions are based on average YOQ-30 and BASC-2 baseline 
scores, and as these scores increase or decrease, then predictions would respond differently 
by allotting more time or less time to the number of sessions required for a student to exhibit 
improvement or recovery depending on which is the therapeutic target. As such, although the 
present study focused on improvement as the main outcome, there is still room to use the 
prediction model to determine when a student might expect to see recovery as well based on 
pre-treatment measure scores. 
Further, the empirical avenues this line of inquiry opens up are of great benefit as 
well. More research investigating different measures that predict for treatment response 
would indicate new uses of such measures. Rather than merely tracking symptoms, measures 
could be used for greater predictive and planning purposes. As highlighted above, clinicians 
who have access to these algorithms can create simple documents (e.g., Microsoft Excel) to 
perform calculations by entering the various subscale scores that have predictive value. 
Finding measures that predict both symptom improvement and symptom deterioration could 
help to guide treatment in new ways. Targeting symptom profiles which predict deterioration 
while trying to build specific adaptive skills which might predict symptom improvement 
could become equally feasible treatment strategies pending further research. Of course it 
must be noted that such algorithms would reflect average treatment response based on pre-
treatment scores, and subsequently should be used only as a guiding tool in treatment 
planning rather than creating unnecessary constriction in the time allotted to reach 
therapeutic benchmarks. 
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Limitations 
This study has several limitations, the first of which was a relatively small sample 
size, which may have particularly limited the statistical power for determining whether 
BASC-2 subscales can determine overall treatment response. Future research can amend this 
issue by recruiting a larger pool of participants to increase statistical power. A second 
limitation was the amount of missing data across the sample. The accuracy of MLM when 
accounting for missing data relies on the amount of actual data present within the study. As 
such, when predicting YOQ-30 change score for sessions where only 25% of actual data is 
available (i.e., session 14), results will inherently be limited. Addressing such a limitation can 
be done simply by requiring participants to complete outcome measures at each session. 
Another limitation would be the variable session numbers across the sample, and the 
non-manualized treatment approach of the ASC Center. The ASC Center is a SMH program 
which aims to provide treatment to any student who seeks it, and so creating a highly 
controlled treatment regimen to be applied across students of different ages, academic levels, 
symptom presentations, clinical severities, socioeconomic backgrounds, family dynamics, 
and so on can become constrained in such naturalistic settings. The main drawback of this 
approach is that variables of treatment can vary from one student to the next, including the 
number of sessions in treatment and the specific techniques utilized for a given presenting 
problem (e.g., individual treatment, crisis intervention, family consultation). Future research 
may aim to address this by offering additional levels of control not offered by the ASC 
Center, such as standardized treatment lengths and manualized procedures. 
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A final limitation was the focus placed on clinical or pathological symptoms. A 
promising area of study would be to explore measures that reflect more adaptive areas of 
functioning and their relationship to outcome. While the BASC-2 does include subscales that 
are described as “adaptive,” the BASC-2 Self-Report does not include “resilience” subscales. 
An attempt was made to investigate the relationship between potential proxies for resilience 
on the Self-Report BASC-2 (e.g., Self-Reliance), but the results were inconclusive and 
complicated by the questionable construct validity of the subscale label. Although beyond the 
scope of the present study, future research should advance our understanding of the 
relationship between resilience and outcome.   
Indeed, the concept of resilience and attempts to study further its implications for 
youth has already been undertaken in school contexts (e.g., Dray et al., 2014). Such research 
attempts to find ways to help adolescents maintain positive mental health outcomes despite 
the presence of adverse life events. It is has been proposed that higher levels of resilience 
serve to counterbalance pathological symptoms and characteristics or help adolescents 
continue to function more adaptively in the presence of these risk factors (Noltemeyer & 
Bush, 2013). Unfortunately, much of the mental health literature places greater focus on 
pathology than resilience, and consequently less is known about resiliency and its potential 
impact in facilitating stronger therapeutic effects across pathological presentations (Harvey & 
Delfabbro, 2004). Future research should better assess components of resiliency and its 
relationship with pathological symptoms and outcomes. 
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Summary 
In conclusion, the results from the present study suggest that CBT is associated with 
rapid symptom improvement for adolescents receiving CBT in a SMH setting as the average 
adolescent experienced a 10-point decrease on the YOQ-30 within just three sessions. 
Further, adolescents receiving CBT in the context of a SMH program typically experience 
even more benefits over the course of 14 sessions of treatment, many of which will be 
classified as either “improved” or “recovered” based on established RCI criteria. Further, the 
rate of improvement is impacted by baseline scores such that relatively higher scores on the 
YOQ-30 predict a faster treatment response whereas relatively higher scores on the BASC-2 
Depression and Hyperactivity subscales predict a worsened response to treatment. These 
findings not only advance our understanding of dose response to CBT in SMH settings, but 
they create opportunities to better inform, individualize, and prescribe effective treatment 
strategies in similar contexts.   
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Table 1. Descriptive Statistics of Baseline BASC-2 Scores 
 
BASC-2 Subscale N Minimum Maximum Mean Standard Deviation 
Atypicality 133 40 116 60.47 14.62 
Locus of Control 133 36 87 62.19 11.51 
Social Stress 133 36 93 62.93 12.75 
Anxiety 133 35 88 67.07 11.65 
Depression 133 40 93 65.92 12.80 
Inadequacy 133 40 96 65.81 13.29 
Somatization 133 40 89 62.47 14.16 
Attention Problems 133 31 82 61.17 11.60 
Hyperactivity 133 38 87 57.48 11.11 
 
Table 1.   Mean scores are presented as T-scores. At-risk scores are defined as T-scores between 60 
and 69, and clinically elevated scores are defined as T-scores of 70 or higher. 
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Table 2. Change in -2LL and Residual Estimate by Model 
Model Parameters -2LL -2LL 
Change 
AIC BIC Residual  
Estimate 
Residual 
Estimate 
Percent Change 
I 2 6487.23 n/a 6491.23 6500.51 285.22*** n/a 
II 3 5989.42 -497.81** 5995.42 6009.33 99.65*** -65.10% 
III 4 5864.08 -125.34** 5872.08 5890.63 80.76*** -19.0% 
IV 5 5744.93 -119.15** 5754.93 5778.12 56.19*** -30.42% 
V 6 5736.04 -8.89** 5748.04 5775.87 55.72*** -0.84% 
VI 7 5731.53 -4.51* 5745.53 5778.00 55.23*** -0.88% 
VII 8 5717.80 -13.73** 5733.80 5770.91 55.23*** 0% 
VIII 10 5702.03 -15.77** 5722.03 5768.42 55.24*** +0.02% 
 
Table 2.   * p < .05.  ** p < .01.  *** p < .001; -2LL Change and Residual Estimate Percent Change for 
each row based on model preceding it. 
 
Model I – Fixed: intercepts 
Model II – Fixed: intercepts; Random: intercepts 
Model III – Fixed: intercepts, sessions; Random: intercepts 
Model IV – Fixed: intercepts, sessions; Random: intercepts, sessions 
Model V – Fixed: intercepts, sessions, quadratic sessions; Random: intercepts, sessions 
Model VI – Fixed: intercepts, sessions, quadratic sessions, cubic sessions; Random: intercepts, sessions 
Model VII – Fixed: intercepts, sessions, quadratic sessions, cubic sessions, YOQ-30 baseline; Random: 
intercepts, sessions 
Model VIII – Fixed: intercepts, sessions, quadratic sessions, cubic sessions, YOQ-30 BL, Depression BL, 
Hyperactivity BL; Random: intercepts, sessions 
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Table 3. Parameter Estimates for the Eight Models Determining the Relationship Between Pre-treatment Measure Scores 
and Treatment Response 
 
 Model  
I 
Model  
II 
Model  
III 
Model  
IV 
Model  
V 
Model  
VI 
Model  
VII 
Model VIII 
Fixed Components         
Intercept 16.65*** 15.94*** 10.24*** 9.41*** 7.94*** 6.92*** 7.03*** 7.05*** 
Session   1.22*** 1.57*** 2.44*** 3.71*** 3.66*** 3.67*** 
Session
2
     -0.08** -0.37** -0.36** -0.36** 
Session
3
      0.02* 0.02* 0.02* 
YOQ-30       0.29*** 0.54*** 
BASC-Depression        -0.41*** 
BASC-Hyperactivity        -0.19† 
         
Random Components         
Intercept  180.44*** 196.62*** 150.22*** 155.72*** 156.58*** 137.57*** 119.30*** 
Session    2.40*** 2.16*** 2.16*** 2.17*** 2.15*** 
 
Table 3.   † p < .10.  * p < .05.  ** p < .01.  *** p < .001. 
 
Model I – Fixed: intercepts 
Model II – Fixed: intercepts; Random: intercepts 
Model III – Fixed: intercepts, sessions; Random: intercepts 
Model IV – Fixed: intercepts, sessions; Random: intercepts, sessions 
Model V – Fixed: intercepts, sessions, quadratic sessions; Random: intercepts, sessions 
Model VI – Fixed: intercepts, sessions, quadratic sessions, cubic sessions; Random: intercepts, sessions 
Model VII – Fixed: intercepts, sessions, quadratic sessions, cubic sessions, YOQ-30 baseline; Random: intercepts, sessions 
Model VIII – Fixed: intercepts, sessions, quadratic sessions, cubic sessions, YOQ-30 BL, Depression BL, Hyperactivity BL; Random: intercepts, 
sessions 
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Table 4. Process of BASC-2 Subscale Model Inclusion 
 
Baseline measure Step 1 Step 2 Step 3 Step 4 Step 5 Step 6 Step 7 Step 8 
YOQ-30  
Total Score 
0.52 
(.000) 
0.52 
(.000) 
0.52 
(.000) 
0.53 
(.000) 
0.53 
(.000) 
0.53 
(.000) 
0.55 
(.000) 
0.54 
(.000) 
BASC-2  
Depression 
-0.40 
(.008) 
-0.40 
(.004) 
-0.38 
(.002) 
-0.38 
(.003) 
-0.37 
(.003) 
-0.39 
(.001) 
-0.37 
(.002) 
-0.41 
(.000) 
BASC-2  
Hyperactivity 
-0.17 
(.178) 
-0.17 
(.179) 
-0.17 
(.162) 
-0.16 
(.172) 
-0.15 
(.185) 
-0.15 
(.164) 
-0.15 
(.172) 
-0.19 
(.058) 
BASC-2  
Atypicality 
-0.10 
(.302) 
-0.10 
(.304) 
-0.10 
(.307) 
-0.10 
(.305) 
-0.10 
(.291) 
-0.11 
(.238) 
-0.93 
(.303) 
 
BASC-2  
Somatization 
0.07 
(.486) 
0.07 
(.488) 
0.07 
(.495) 
0.08 
(.323) 
0.09 
(.317) 
0.08 
(.324) 
  
BASC-2  
Locus of Control 
-0.05 
(.638) 
-0.05 
(.646) 
-0.05 
(.655) 
-0.5 
(.639) 
-0.05 
(.615) 
   
BASC-2  
Attention Problems 
0.04 
(.754) 
0.04 
(.765) 
0.05 
(.668) 
0.04 
(.704) 
    
BASC-2  
Anxiety 
0.04 
(.771) 
0.04 
(.756) 
0.04 
(.715) 
     
BASC-2  
Inadequacy 
0.02 
(.900) 
0.02 
(.905) 
      
BASC-2  
Social Stress 
0.02 
(.906) 
       
 
Table 4. Each cell indicates the unstandardized regression weight with the p-value in parentheses. The 
values in bold at the bottom of each column corresponds to the BASC-2 subscale removed from subsequent 
analyses; Step 8 contains the final unstandardized regression weights and p-values for the subscales retained 
for analyses. 
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Figure 1. Frequency of At-risk and Clinical Baseline BASC-2 Scores
 
Figure 1. At-risk scores are defined as T-scores between 60 and 69, and clinically elevated scores are 
defined as T-scores of 70 or higher. N = 133. 
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Figure 2. Overall Treatment Response for the Entire Sample 
 
 
 
Figure 2. Treatment response based solely on session number data. The increase in YOQ-30 Change is a reflection of symptom 
improvement, where a higher number indicates a greater level of improvement. The horizontal dotted line represents the cut-off 
for reliable change. 
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Figure 3. Examples of Varying Treatment Responses According to Different Pre-treatment Measure Scores 
 
Figure 3. In reference to the key: Y = YOQ-30, D = BASC-2 Depression subscale, and H = BASC-2 Hyperactivity subscale; the first line (i.e., 
YOQ-30 = 48) represents the average baseline scores for the sample. The increase in YOQ-30 change is a reflection of symptom improvement, 
where a higher number indicates a greater level of improvement. The horizontal dotted line represents the cut-off for reliable change. 
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Appendix A 
To: Kurt Michael  
Psychology  
EMAIL  
 
From: Dr. Stan Aeschleman, Institutional Review Board Chairperson 
RE: Notice of IRB Approval by Expedited Review (under 45 CFR 46.110) 
Date: 8/07/2013 
Study #: 13-0020 
Sponsors: Ashe County Board of Education: 13-0283    
Study Title: Student Educational and Emotional Development (SEED) Study 
Submission Type: Renewal 
Expedited Category: (6) Collection of Data from Recordings made for Research 
Purposes,(7) Research on Group Characteristics or Behavior, or Surveys, Interviews, etc. 
Renewal Date:  8/07/2013 
Expiration Date of Approval: 8/06/2014  
 
The Institutional Review Board (IRB) renewed approval for this study for the period 
indicated above. The IRB found that the research procedures meet the expedited category 
cited above. IRB approval is limited to the activities described in the IRB approval materials, 
and extends to the performance of the described activities in the sites identified in the IRB 
application. In accordance with this approval, IRB findings and approval conditions for the 
conduct of this research are listed below.  
 
Regulatory and other findings: 
 
The IRB has determined that the research presents minimal risks to participants, adequate 
provisions are made for soliciting assent of minors, and obtaining the consent of one parent 
or guardian (45 CFR 46.408).  
 
Approval Conditions:  
 
Appalachian State University Policies: All individuals engaged in research with human 
participants are responsible for compliance with the University policies and procedures, and 
IRB determinations.  
 
Principal Investigator Responsibilities: The PI should review the IRB's list of PI 
responsibilities. The Principal Investigator (PI), or Faculty Advisor if the PI is a student, is 
ultimately responsible for ensuring the protection of research participants; conducting sound 
ethical research that complies with federal regulations, University policy and procedures; and 
maintaining study records.  
 
Modifications and Addendums: IRB approval must be sought and obtained for any proposed 
modification or addendum (e.g., a change in procedure, personnel, study location, study 
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instruments) to the IRB approved protocol, and informed consent form before changes may 
be implemented, unless changes are necessary to eliminate apparent immediate hazards to 
participants. Changes to eliminate apparent immediate hazards must be reported promptly to 
the IRB.  
 
Approval Expiration and Continuing Review: The PI is responsible for requesting continuing 
review in a timely manner and receiving continuing approval for the duration of the research 
with human participants. Lapses in approval should be avoided to protect the welfare of 
enrolled participants. If approval expires, all research activities with human participants must 
cease.  
 
Prompt Reporting of Events: Unanticipated Problems involving risks to participants or 
others; serious or continuing noncompliance with IRB requirements and determinations; and 
suspension or termination of IRB approval by external entity, must be promptly reported to 
the IRB.  
 
Closing a study: When research procedures with human subjects are completed, please 
complete the Request for Closure of IRB review form and send it to irb@appstate.edu.  
 
Websites:  
 
1. PI responsibilities: 
http://researchprotections.appstate.edu/sites/researchprotections.appstate.edu/files/PI%20Res
ponsibilities.pdf  
 
2. IRB forms: http://researchprotections.appstate.edu/human-subjects/irb-forms  
 
CC: 
John Jameson, Psychology 
Cameron Massey, Psychology 
Rafaella Sale 
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Appendix B 
Student Participant Consent Forms 
 
Assessment, Support, and Counseling (ASC) Center: Ashe County High School 
Informed Consent for Clinical Services 
 
We are pleased to have the opportunity to serve you and/or your child through the ASC 
(Assessment, Support, and Counseling) Center, a partnership between Ashe County High 
School and Appalachian State University (ASU). ASC Center personnel are committed to 
providing the highest quality clinical services to students and their families, providing 
education and training for faculty and staff, and expanding the knowledge base for best 
practice standards through research. Clinical services are provided by qualified, licensed 
professional providers, faculty members, and/or students under supervision, as appropriate. 
As we proceed to work together, the following information may be helpful.  
 
Depending on your situation, our first few sessions might be spent exploring and assessing 
your problems and the possible reasons for them. This might include written or oral testing 
and evaluation. Once we understand your issues to the best of our ability, you and we will 
agree on the goals you want to accomplish. Together, we may also agree to change the goals 
as we move along. We may set some time frames for action. 
 
ASU/ASC providers/faculty and students will work to ensure that the theoretical 
perspectives, interventions, and treatments used are considered the best practice methods, 
supported by research, and are appropriate for your needs. However, it is important for you to 
know that there are often many different approaches to similar problems. We will talk with 
you about the pros and cons of each approach before a decision is made to go ahead with any 
treatment plan. Successful treatment or problem resolution requires a commitment from you. 
There is always the possibility that our work will not result in the progress we hope to make. 
Please let us know immediately if you have any questions or concerns. 
 
CONFIDENTIALITY 
 
Ordinarily, anything and everything you share with us is strictly confidential—whether you 
say it in person, on the telephone, or write it. Some of the information you give us about 
yourself and matters we discuss will be recorded in your clinical record. If we mutually 
decide that, in your interests, ASU/ASC Center personnel should provide some part of your 
confidential information to another professional, your insurance company, your attorney, or 
even you, you will sign a specific and time-limited release of information. You will know 
what is to be released, to whom, and how the information will be used. You will be able to 
stipulate the time period in which the release is to be in effect. 
 
There are some circumstances in which ASU/ASC Center providers, faculty, and/or students 
would be required by law to reveal confidential information about you without your consent. 
One situation would be if we learned that you were at imminent risk of harming yourself or 
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another person. Another situation would be if there is reasonable suspicion of abuse or 
neglect of a child. A third situation would be in the event of a court order compelling us to 
release your clinical record to a court of law. Other situations would be based on federal or 
state laws. Some of these situations are discussed in a separate document, the Notice of 
Privacy Practices, which we are providing as required by federal law.  
 
Sound clinical practice and teaching includes consultation and discussion with other 
interdisciplinary providers, faculty members, and students, sometimes regarding specific 
cases. All those affiliated with ASU/ASC Center are also legally bound to keep the 
information confidential. If you do not object, we will not tell you about these consultations 
and discussion unless they are important to our work together. 
 
RESEARCH PARTICIPATION 
 
As indicated above, we endeavor to use best practices when providing treatment to students. 
In order to accomplish this, we regularly collect data on treatment progress, satisfaction, 
academic outcomes, attendance, and disciplinary referrals. Although we use these data to 
facilitate best practices, participation in this type of data collection in no way reduces our 
commitment to protecting students’ confidentiality. On occasion, we conduct specific 
research projects above and beyond these normal methods of data collection. If selected for a 
project beyond routine data collection, a separate consent form will be obtained and 
additional information provided for parent/guardian and student consideration. 
 
HOW TO REACH ASC CENTER PROVIDERS, FACULTY, AND STUDENTS 
 
If it is necessary to cancel or reschedule an appointment, please do so at least 24 hours in 
advance. Please cancel your appointment by calling (336)846-2400, between 8:30 a.m. and 
3:30 p.m., Monday through Friday. If your call is urgent or an emergency, please tell the 
operator 
immediately. If you have an imminent emergency, you may also contact the Ashe County 
HELP line, at 264-4325, call 911, or go to any hospital emergency room. We will discuss 
other ways of dealing with crisis situations relevant to your personal situation, as needed. 
 
Feel free to contact Dr. Kurt Michael, Licensed Psychologist, Professor of Psychology (828-
262-2272, ext. 432), or Tara Miller, ASC Center Coordinator (336-846-2400), if you have 
questions or comments regarding clinical services. 
 
I have received and been given the opportunity to read a copy of this Informed Consent for 
Clinical Services sheet. 
 
Signature of Legally Responsible Person or Student:  
 
_________________________________________________________ Date: 
_____________ 
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Specify Relationship to Student and Print Name in Full:  
 
__________________________________________________________________________ 
 
Additional Signature of Child or Parent, if needed:  
 
__________________________________________________________ Date: 
______________ 
 
Witness (optional):  
 
__________________________________________________________ Date: 
______________ 
 
 
___ Copy given to Student ___ Student declined copy 
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NOTICE OF PRIVACY PRACTICES 
 
THIS NOTICE DESCRIBES HOW MEDICAL INFORMATION ABOUT YOU MAY 
BE USED AND DISCLOSED AND HOW YOU 
CAN GET ACCESS TO THIS INFORMATION. 
PLEASE REVIEW THIS NOTICE CAREFULLY. 
 
Your health record contains personal information about you and your health. This 
information about you that may identify you and that relates to your past, present or future 
physical or mental health or condition and related health care services is referred to as 
Protected Health Information 
(“PHI”). This Notice of Privacy Practices describes how the ASC Center may use and 
disclose your PHI in accordance with applicable law. It also describes your rights regarding 
how you may gain access to and control your PHI. 
 
The ASC Center is required by law to maintain the privacy of PHI and to provide you with 
notice of our legal duties and privacy practices with respect to PHI. The ASC Center is 
required to abide by the terms of this Notice of Privacy Practices. We reserve the right to 
change the terms of this Notice of Privacy Practices at any time. Any new Notice of Privacy 
Practices will be effective for all PHI that we maintain at that time. The ASC Center will 
provide you with a copy of the revised Notice of Privacy Practices by sending a copy to you 
in the mail upon request or providing one to you at your next appointment. 
 
HOW the ASC Center MAY USE AND DISCLOSE HEALTH INFORMATION 
ABOUT YOU 
 
For Treatment. Your PHI may be used and disclosed by those who are involved in your 
care for the purpose of providing, coordinating, or managing your health care treatment and 
related services. This includes consultation with other ASC Center clinical providers, faculty, 
supervised 
students, or other treatment team members, if applicable. We may disclose PHI to any other 
consultant only with your authorization. 
 
For Payment. The ASC Center may use and disclose PHI so that we can receive payment 
for the treatment services provided to you. This will only be done with your authorization. 
Examples of payment-related activities are: making a determination of eligibility or coverage 
for insurance benefits, processing claims with your insurance company, reviewing services 
provided to you to determine medical necessity, or undertaking utilization review activities. 
If it becomes necessary to use collection processes due to lack of payment for services, the 
ASC Center will only disclose the minimum amount of PHI necessary for purposes of 
collection. 
 
For Health Care Operations. The ASC Center may use or disclose, as needed, your PHI in 
order to support our business activities including, but not limited to, quality assurance 
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activities, evaluation of effectiveness, licensing, and conducting or arranging for other 
business activities. 
For example, we may share your PHI with third parties that perform various business 
activities (e.g., billing services) provided we have a written contract with the business that 
requires it to safeguard the privacy of your PHI. We may disclose your PHI to other ASC 
Center clinical 
providers, faculty, supervised students, and/or other treatment team members for training or 
teaching purposes. 
 
Required by Law. Under the law, the ASC Center must make disclosures of your PHI to 
you upon your request. In addition, we must make disclosures to the Secretary of the 
Department of Health and Human Services for the purpose of investigating or determining 
the ASC Center’s compliance with the requirements of the Privacy Rule. 
 
Without Authorization. Applicable law and ethical standards permit the ASC Center to 
disclose information about you without your authorization only in a limited number of other 
situations. The types of uses and disclosures that may be made without your authorization are 
those that are: 
 Required by Law, such as the mandatory reporting of child abuse or neglect or 
mandatory government agency audits or investigations (such as the psychology or 
social work licensing boards or the health department) 
 Required by Court Order 
 Necessary to prevent or lessen a serious and imminent threat to the health or safety of 
a person or the public. If information is disclosed to prevent or lessen a serious threat 
it will be disclosed to a person or persons reasonably able to prevent or lessen the 
threat, including the target of the threat. 
 
Verbal Permission. The ASC Center may use or disclose your information to family 
members who are directly involved in your treatment with your verbal permission. 
 
With Authorization. Uses and disclosures not specifically permitted by applicable law will 
be made only with your written authorization, which you may revoke at any time. 
 
YOUR RIGHTS REGARDING YOUR PHI 
 
You have the following rights regarding PHI the ASC Center maintains about you. To 
exercise any of these rights, please submit your request in 
writing to us at the address below or in person. 
 Right of Access to Inspect and Copy. You have the right, which may be restricted 
only in exceptional circumstances, to inspect and copy PHI that may be used to make 
decisions about your care. Your right to inspect and copy PHI will be restricted only 
in those situations where there is compelling evidence that access would cause serious 
harm to you. The ASC Center may charge a reasonable, cost-based fee for copies. 
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 Right to Amend. If you feel that the PHI the ASC Center has about you is incorrect 
or incomplete, you may ask us to amend the information although we are not required 
to agree to the amendment. 
 Right to an Accounting of Disclosures. You have the right to request an accounting 
of certain of the disclosures that the ASC Center makes of your PHI. The ASC Center 
may charge you a reasonable fee if you request more than one accounting in any 12-
month period. 
 Right to Request Restrictions. You have the right to request a restriction or 
limitation on the use or disclosure of your PHI for treatment, payment, or health care 
operations. We are not required to agree to your request. 
 Right to Request Confidential Communication. You have the right to request that 
the ASC Center communicates with you about medical matters in a certain way or at 
a certain location. 
 Right to a Copy of this Notice. You have the right to a copy of this notice. 
 
COMPLAINTS 
 
If you believe the ASC Center has violated your privacy rights, you have the right to file a 
complaint in writing to us at the address below or in person or with the Secretary of Health 
and Human Services at 200 Independence Avenue, S.W., Washington, D.C. 20201 or by 
calling (202) 619-0257. 
 
The effective date of this Notice is March 3, 2014. 
 
Notice of Privacy Practices 
Receipt and Acknowledgment of Notice 
 
 
 
Name_____________________________________________ DOB: 
______________________ 
 
I hereby acknowledge that I have received and have been given an opportunity to read a copy 
of the ASC Center Notice of Privacy Practices. I understand that if I have any questions 
regarding the Notice or my privacy rights, I can contact my provider, Tara Miller, or Dr. Kurt 
Michael at the address or phone number below or discuss them in person at my next 
appointment. 
 
Signature of Legally Responsible Person or Student*:  
 
____________________________________________________Date:________________ 
 
Specify Relationship to Student and Print Name in Full:  
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___________________________________________________ 
 
* If you are signing as a personal representative of an individual, please describe your legal 
authority to act for this individual (power of attorney, healthcare surrogate, etc.). 
 
Additional Signature of Student or Parent, if needed:  
 
______________________________________________________Date:________________ 
 
Witness (optional):  
 
_________________________________________________________ 
Date:________________ 
 
Student Refuses to Acknowledge Receipt 
 
Signature of Staff Member:  
 
_________________________________________________________ 
Date:________________ 
 
 
The ASC Center 
Ashe County High School 
West Jefferson, NC 28694 
Tara Miller: (336) 846-2400 
Kurt Michael: (828) 262-2272, ext. 432 
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Authorization for Use and Disclosure of Protected Health Information 
 
This form implements the requirements for student authorization to use and disclose health 
information protected by the federal health privacy law (45 C.F.R. parts 160, 164), the 
federal drug and alcohol confidentiality law (42CFR, part 2) and state confidentiality law 
governing mental health, developmental disabilities, and substance abuse services (GS 122C) 
 
 
Student Name: _____________________________________ Date of Birth: 
________________ 
 
I hereby authorize: ASC Center/Appalachian State University Licensed Professional 
Providers, Faculty Members, and/or Supervised Students To Disclose and/or Share Protected 
Health Information with: Ashe County Schools 
 
The following protected information: (Provide a specific and meaningful description of the 
information to be used or disclosed) Psychological evaluation results, student status, 
participation in services, progress made, family dynamics and history, safety issues, 
recommendations, school status, school concerns, grades, testing, behavioral concerns, 
school progress, treatment plan, clinical impressions 
 
The Purpose of Disclosure: Coordination of services, participation in the School-Based 
Therapy and ASC Center Programs, and treatment planning. 
 
REDISCLOSURE 
 
Once information is disclosed pursuant to this signed authorization, I understand that the 
federal health privacy law (45 C.F.R. Part 164) protecting health information may not apply 
to the recipient of the information and, therefore, may not prohibit the recipient from 
redisclosing it. Other laws, however, may prohibit redisclosure. When this agency discloses 
mental health and developmental disabilities information protected by state law (G.S. 122C) 
or substance abuse treatment information protected by federal law (42 C.F.R. Part 2), it must 
inform the recipient of the information that redisclosure is prohibited except as permitted or 
required by these two laws. ASU Institute for Health and Human Services Notice of Privacy 
Practices describes the circumstances when disclosure is permitted or required by these laws. 
 
EXPIRATION AND REVOCATION 
 
I understand that, with certain exceptions, I have the right to revoke this authorization at any 
time. [If I want to revoke this authorization, I must do so in writing.] If not revoked earlier, 
this authorization expires automatically upon ____________________________ or one year 
from the date it is signed, whichever is earlier. 
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NOTICE OF VOLUNTARINESS 
 
I understand that I may refuse to sign this authorization form. A readable photocopy or fax of 
this authorization shall have the same force and effect 
as this original. 
 
SIGNATURES 
 
Signature of Legally Responsible Person:  
 
__________________________________________________________ Date: 
______________ 
 
Specify Relationship to Student and Print Name in Full: 
 
____________________________________________________________________ 
 
Signature of Student:  
 
_________________________________________________________ Date: 
_______________ 
 
Additional Parent/Guardian Signature:  
 
_________________________________________________________ Date: 
_______________ 
 
Witness (optional):  
 
_________________________________________________________ Date: 
_______________ 
 
 
___ Copy given to Parent/guardian/student ___ Parent/guardian/student declined copy 
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Daymark Recovery Services 
Authorization for Use and Disclosure of Protected Health Information 
 
This form implements the requirements for student authorization to use and disclose health 
information protected by the federal health privacy law (45 C.F.R. parts 160, 164), the 
federal drug and alcohol confidentiality law (42CFR, part 2) and state confidentiality law 
governing mental health, developmental disabilities, and substance abuse services (GS 122C) 
 
 
Student Name: __________________ Student ID: ___________ Date of Birth: 
______________ 
 
I hereby authorize Daymark Recovery Services 
 
To _X Disclose and/or _X Share Protected Health Information with Ashe County School 
System 
 
The following protected information: Psychological evaluation results, student status, 
participation in services, progress made, family dynamics and history, safety issues, 
recommendations, school status, school concerns, grades, testing, behavioral concerns, 
school progress, treatment plan, clinical impressions The Purpose of & Disclosure: 
Coordination of services, participation in the School-Based Therapy and Assessment, 
Support, and Counseling (ASC) Center Programs, and treatment planning. 
 
REDISCLOSURE 
 
Once information is disclosed pursuant to this signed authorization, I understand that the 
federal health privacy law (45 C.F.R. Part 164) protecting health information may not apply 
to the recipient of the information and, therefore, may not prohibit the recipient from 
redisclosing it. Other laws, however, may prohibit redisclosure. When this agency discloses 
mental health and developmental disabilities information protected by state law (G.S. 122C) 
or substance abuse treatment information protected by federal law (42 C.F.R. Part 2), it must 
inform the recipient of the information that redisclosure is prohibited except as permitted or 
required by these two laws. Daymark Recovery Services’ Notice of Privacy Practices 
describes the circumstances when disclosure is permitted or required by these laws. 
 
EXPIRATION AND REVOCATION 
 
I understand that, with certain exceptions, I have the right to revoke this authorization at any 
time. [If I want to revoke this authorization, I must do so in writing.] The procedure for how I 
may revoke this authorization, as well as the exceptions to my right to revoke, are explained 
in Daymark Recovery Services’ Notice of Privacy Practices, a copy of which has been 
provided to me. If not revoked earlier, this authorization expires automatically upon 
__________________ or one year from the date it is signed, whichever is earlier. 
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NOTICE OF VOLUNTARINESS 
 
I understand that I may refuse to sign this authorization form. If I choose not to sign this 
form, I understand that Daymark Recovery Services cannot deny or refuse to provide 
treatment, payment enrollment in a health plan, or eligibility for benefits due to my refusal to 
sign. A readable photocopy or fax of this authorization shall have the same force and effect 
as this original. 
 
Signature of Legally Responsible Person or Student:  
 
__________________________________________________________ Date: 
______________ 
 
 
Specify Relationship to Consumer and Print Name in Full:  
 
_______________________________________________________________________ 
 
Additional Signature of Child or Parent, if needed:  
 
____________________________________________________________Date:__________
___ 
 
Witness (optional):  
 
____________________________________________________________Date: 
_____________ 
 
___ Copy given to Consumer ___ Consumer declined copy 
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Daymark Recovery Services 
 
This form implements the requirements for student authorization to use and disclose health 
information protected by the federal health privacy law (45 C.F.R. parts 160, 164), the 
federal drug and alcohol confidentiality law (42CFR, part 2) and state confidentiality law 
governing mental health, developmental disabilities, and substance abuse services (GS 122C) 
 
Student Name: ____________________ Student ID: ___________ Date of Birth: 
___________ 
 
I hereby authorize Daymark Recovery Services To _X Disclose and/or _X Share Protected 
Health Information with ASU Licensed Providers 
 
The following protected information: Psychological evaluation results, student status, 
participation in services, progress made, family dynamics and history, safety issues, 
recommendations, school status, school concerns, grades, testing, behavioral concerns, 
school progress, treatment plan, clinical impressions The Purpose of & Disclosure: 
Coordination of services, participation in the School-Based Therapy and Assessment, 
Support, and 
Counseling (ASC) Center Programs, and treatment planning. 
 
REDISCLOSURE 
 
Once information is disclosed pursuant to this signed authorization, I understand that the 
federal health privacy law (45 C.F.R. Part 164) protecting health information may not apply 
to the recipient of the information and, therefore, may not prohibit the recipient from 
redisclosing it. Other laws, however, may prohibit redisclosure. When this agency discloses 
mental health and developmental disabilities information protected by state law (G.S. 122C) 
or substance abuse treatment information protected by federal law (42 C.F.R. Part 2), it must 
inform the recipient of the information that redisclosure is prohibited except as permitted or 
required by these two laws. Daymark Recovery Services’ Notice of Privacy Practices 
describes the circumstances when disclosure is permitted or required by these laws. 
 
EXPIRATION AND REVOCATION 
 
I understand that, with certain exceptions, I have the right to revoke this authorization at any 
time. [If I want to revoke this authorization, I must do so in writing.] The procedure for how I 
may revoke this authorization, as well as the exceptions to my right to revoke, are explained 
in Daymark Recovery Services’ Notice of Privacy Practices, a copy of which has been 
provided to me. If not revoked earlier, this authorization expires automatically upon 
___________________ or one year from the date it is signed, whichever is earlier. 
 
NOTICE OF VOLUNTARINESS 
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I understand that I may refuse to sign this authorization form. If I choose not to sign this 
form, I understand that Daymark Recovery Services cannot deny or refuse to provide 
treatment, payment enrollment in a health plan, or eligibility for benefits due to my refusal to 
sign. A readable photocopy or fax of this authorization shall have the same force and effect 
as this original. 
 
Signature of Legally Responsible Person or Student:  
 
__________________________________________________________ Date: 
_____________ 
 
Specify Relationship to Consumer and Print Name in Full:  
 
________________________________________________________________________ 
 
Additional Signature of Child or Parent, if needed:  
 
____________________________________________________________Date:__________
___ 
 
Witness (optional):  
 
____________________________________________________________Date:__________
___ 
 
___ Copy given to Consumer ___ Consumer declined copy 
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Ashe High School/Appalachian State University 
Informed Consent for Participation in Research 
 
Title of Project: The Effectiveness of the Assessment, Support, and Counseling (ASC) 
Center 
Investigator(s): Dr. Kurt Michael, Carissa Orlando, M.A., Kelsey Toomey, M.A. 
 
I. Purpose of Research: 
As described on the Consent to Treatment form that was signed and on-file at the ASC 
Center, we are committed to providing your children with effective interventions to address 
their behavioral and academic concerns. As you are already aware, we regularly collect data 
on treatment progress, satisfaction, academic outcomes, attendance, and disciplinary referrals 
that help us serve your children better. We now request your permission to present 
anonymous data regarding the effects of ASC Center services in the form of presentations 
and publications to an 
audience of professionals outside of the ASC Center. Information about the effects of the 
ASC Center services will be presented anonymously so that your children’s identities will 
not be disclosed. 
 
II. Procedures: 
In addition to the information collected regularly as part of ASC Center involvement, 
students and parents will be asked to complete a few brief assessments before, during, and 
after ASC Center services have been delivered. The assigned ASC Center clinician will 
review these documents in detail with the students and parents (before and after) and if there 
is evidence on the assessments of significant distress or discomfort, interventions will be 
delivered (or referrals made) immediately, up to and including the disclosure of this 
information to parents/guardians should it deemed consistent with the “limits of 
confidentiality” described on the original 
Consent to Treatment Form (that is, danger to self or others, reasonable suspicion of abuse). 
 
III. Risks: 
As described above, the risks of participation in this project do not exceed the normal risks 
associated with receiving mental health/behavioral treatment in other settings. We will abide 
by all standards of confidentiality and we are committed to the safe and effective treatment of 
your children’s concerns. 
 
IV. Benefits: 
Your participation in this project will help other professionals and society at large learn more 
about providing effective mental health and behavioral treatment for high school students. 
 
V. Extent of Anonymity and Confidentiality: 
The answers you and your student provide on the assessments will be kept confidential and 
under lock and key. Only authorized ASC Center personnel will know the identity of your 
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children. When the data is presented, it will not include your children’s identity. The 
information will be presented anonymously. 
 
VI. Compensation: 
There will not compensation for your participation. ASC Center services are provided at no 
cost to you or your child. 
 
 
VII. Freedom to Withdraw: 
You or your child do not have to answer any questions if you do not want to and you can stop 
at any time. 
 
VIII. Participant's Responsibilities: 
I voluntarily agree to participate in this study. I have the following responsibilities: 
1. Review this consent form 
2. Complete the assessments honestly if I consent to participation 
 
IX. Participant’s Permission: 
I have read and understand the Informed Consent and conditions of this project. I have had 
all my questions answered. I hereby acknowledge the above and give my voluntary consent 
by completing and signing this form. 
Signature of Legally Responsible Person or Student:  
 
_______________________________________ Date: _____________ 
 
Specify Relationship to Student and Print Name in Full: 
 
______________________________________________________ 
 
Signature of Student:  
 
________________________________________ Date: _______________ 
 
 
Should I have any questions about this research or its conduct, I may contact: 
Kurt Michael, michaelkd@appstate.edu, (828) 262-2272, ext. 432 
IRB Administrator, Research and Sponsored Programs, Appalachian State University, 
Boone, NC 28608, (828) 262-2130, irb@appstate.edu. 
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majoring in psychology and minoring in neuroscience. He was accepted to Appalachian State 
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